Bellerophon Therapeutics Inc (LTS:0HMP)
$ 0.037 0 (0%) Market Cap: 673,000.00 Enterprise Value: -14.49 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Bellerophon Therapeutics Inc at JMP Securities Life Science Conference Transcript

Jun 20, 2019 / 03:00PM GMT
Release Date Price: $9.81
Jason Butler
JMP Securities - Analyst

All right. So we are going to go ahead and get started. Yes, okay. Great. So thank you for being with us again at the 2019 JMP Securities Life Science Conference. Excited to have next company presentation here from Bellerophon Therapeutics. Bellerophon is developing novel treatments for lung diseases including peripheral -- PAH.

So Fabian Tenenbaum, CEO, I will turn it over to you. Thank you for being here, Fabian.

Fabian Tenenbaum
Bellerophon Therapeutics, Inc. - CEO

Thank you very much, Jason. Thank you for having us. Before we begin, let me just remind everyone our presentation will contain forward-looking statements. For additional information on those statements, please review our periodical SEC filings.

Bellerophon therapeutics is a clinical stage biotherapeutics company. We are focused on developing inhaled nitric oxide therapies for chronic pulmonary hypertensive diseases. We've developed a unique, proprietary, portable drug delivery system for nitric oxide that provides us with unique

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot